Alfonso Quintas Cardama - Aug 31, 2021 Form 4 Insider Report for TCR2 THERAPEUTICS INC. (TCRR)

Role
Chief Medical Officer
Signature
/s/ Margaret Siegel as Attorney-in-Fact
Stock symbol
TCRR
Transactions as of
Aug 31, 2021
Transactions value $
$65,979
Form type
4
Date filed
12/10/2021, 03:34 PM
Next filing
Nov 18, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TCRR Common Stock Award $2.34K +164 +4.37% $14.26* 3.92K Aug 31, 2021 Direct F1, F2
transaction TCRR Common Stock Options Exercise $31.8K +43K +1098.34% $0.74 46.9K Dec 9, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TCRR Stock Option (Right to Buy) Options Exercise $31.8K +43K $0.74 31.6K Dec 9, 2021 Common Stock 43K $0.74 Direct F3
transaction TCRR Stock Option (Right to Buy) Award $0 +115K $0.00 115K Dec 9, 2021 Common Stock 115K $5.21 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the issuer's 2018 Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of March 1, 2021 through August 31, 2021. This transaction is exempt under Rule 16b-3(c).
F2 In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on August 31, 2021.
F3 25% of this option vested and became exercisable on October 10, 2018, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.
F4 25% of this option shall vest and become exercisable on January 1, 2023, with the remainder vesting in thirty-six (36) equal monthly installments thereafter